Vaccinex (NASDAQ: VCNX) reported Q4 revenue for the quarter came in at $194 thousand versus the consensus estimate of $100 thousand.

“The fourth quarter caps a year of significant progress at Vaccinex, during which we transitioned to a publicly-traded company and continued to advance pepinemab in a number of serious and difficult to treat medical conditions, including cancer and Huntington’s disease,” commented Maurice Zauderer, Ph.D., Chief Executive Officer of Vaccinex. “As we progress through 2019, we are rapidly approaching significant milestones for our Company, with the anticipated release of initial open label data from our ongoing CLASSICAL - Lung trial in non-small cell lung cancer during the second quarter and continuing progress evaluating combination immunotherapy in melanoma.”

“In parallel, we are efficiently advancing pepinemab in our SIGNAL Phase 2 trial for our lead indication, Huntington’s disease, with enrollment in cohort B now completed. The positive results from cohort A demonstrated that pepinemab significantly increased brain metabolic activity with no concerning safety issues, and we believe suggests potential broader clinical utility in other neurodegenerative diseases as well.”

“Finally, we continue to leverage our proprietary ActivMAb antibody discovery platform which we believe offers opportunities for long-term value creation. Of particular interest to our biotech and pharmaceutical partners has been the novel capability to efficiently select antibodies to multi-pass membrane receptors such as GPCR and ion channels, an important class of pharmaceutical products that has, to date, eluded development of antibody drugs,” Dr. Zauderer concluded.

For earnings history and earnings-related data on Vaccinex (VCNX) click here.